Company intelligence / Profile preview

Evoia

Ownership: Private
Employees: ~10
Development stage: Commercial

Overview

Evoia has developed and commercialized a patented technology that converts sustainable raw biomass into plant-beneficial compounds using fire. Their first product, AmpliFYR—a biochar-based seed treatment—has demonstrated increased seedling root and shoot growth and was available in at least 15 states as of late 2022. The company focuses on climate-smart agriculture by providing biostimulants that improve crop resilience to stressors such as climate change while supporting soil health and carbon sequestration.[1][5][6][7]

Therapeutic areas: Other
Modalities: BiostimulantsBiochar-based products
Industry: Agriculture & AgTech

Drug pipeline

1 asset

AmpliFYR

Commercial

Indications: Agricultural seed treatment

Beyond the preview

Go deeper on Evoia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Evoia.

Explore the full profile